Eisai shares new data for Leqembi for Alzheimer’s treatment
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, US on 24-27 October 2023.
The data presented includes information on subcutaneous (SC) formulation including safety and effects on brain amyloid; for example, it was demonstrated that weekly SC administration showed 14% greater amyloid plaque removal than biweekly IV administration, SC pharmacokinetics were higher than IV by 11% and there were lower systemic injection reaction rates with SC compared to IV.
The data also included latest data from Tay Pet Longitudinal substudy, in which 76% of patients showed no decline and 60% showed clinical improvement at 18 months in earlier stage early AD populations. In addition, efficacy results from the Leqembi Clarity AD open-label extension study were shared, demonstrating that patients continued to show benefit after 24 months of treatment.
Finally, the mechanism-based rationale of Leqembi treatment for early AD was shared, showing that dual-acting Leqembi continued to support brain neuron function through the removal of highly toxic proteins (protofibrils) which can cause neuronal injury and death even after plaque removal, providing patients with potential continued benefit.
The company intends to submit a Leqembi SC formulation Biologics License Application (BLA) to the US Food and Drug Administration (FDA) by 31 March 2024.
Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) …
Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which …